Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REG as a therapeutic target

By Bett John S.   Goellner Geoffrey M.   Woodman Ben   Pratt Gregory   Rechsteiner Martin   Bates Gillian P.  

Human Molecular Genetics, Vol. 15, Iss. 1, 2006-01 ,pp. : 33-44

Oxford University Press

Access to resources Recommend Favorite

Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease

By Perry Giselle M.   Tallaksen-Greene Sara   Kumar Ashish   Heng Mary Y.   Kneynsberg Andrew   van Groen Thomas   Detloff Peter J.   Albin Roger L.   Lesort Mathieu  

Human Molecular Genetics, Vol. 19, Iss. 17, 2010-09 ,pp. : 3354-3371

Oxford University Press

Access to resources Recommend Favorite

Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington’s disease mutation

By Fain J.N.  

Human Molecular Genetics, Vol. 10, Iss. 2, 2001-01 ,pp. : 145-152

Oxford University Press

Access to resources Recommend Favorite

Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington’s disease (HD) transgenic mice and HD patients

By Wanker E.E.  

Human Molecular Genetics, Vol. 10, Iss. 21, 2001-10 ,pp. : 2425-2435

Oxford University Press

Access to resources Recommend Favorite

Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice

By Yang Wonsuk   Chen Linan   Ding Yunmin   Zhuang Xiaoxi   Kang Un Jung  

Human Molecular Genetics, Vol. 16, Iss. 23, 2007-12 ,pp. : 2900-2910

Oxford University Press

Access to resources Recommend Favorite